Corporate Calendar 2026

Date	Details
March 26	Publication Annual Report 2025 and 20-F 2025
April 28	Annual Shareholders’ meeting
May 6	First quarter 2026 results (call on May 7, 2026)
August 10	Half Year 2026 results
November 12	Third quarter 2026 results

Key Financials

Consolidated Key Figures

(thousands of €, if not stated otherwise)	Six months ended June 30, 2026	Six months ended June 30, 2025	Year ended December 31, 2025
Income statement
Supply revenues	14.049	18.486	29.924
Collaboration revenues	4.542	121.779	1.082.324
Total net revenues	18.591	140.265	1.112.248
Cost of sales	(13.944)	(18.435)	(29.736)
R&D expenses	(56.486)	(278.027)	(459.421)
S&M, G&A expenses	(58.010)	(74.470)	(153.433)
Impairment of the cell therapy activities	–	–	(228.112)
Other operating income	2.635	14.932	53.493
Operating profit/loss (-)	(107.214)	(215.735)	295.039
Net financial results	123.184	(45.056)	5.832
Taxes	(140)	1.788	18.621
Net profit/loss (-) from continuing operations	15.830	(259.003)	319.492
Net profit from discontinued operations, net of tax	771	(148)	1.392
Net profit/loss (-)	16.601	(259.151)	320.884
Balance sheet
Cash and cash equivalents	135.952	71.669	87.868
Financial investments	2.103.597	3.019.835	2.910.180
R&D incentives receivables	125.713	147.672	157.870
Assets	3.351.188	3.818.224	3.406.518
Shareholders’ equity	3.263.630	2.643.819	3.235.868
Deferred income	33	954.066	32
Other liabilities	87.525	220.339	170.618
CASH FLOW
Operational cash burn (*)	(63.617)	(91.529)	(189.141)
Cash flow used in operating activities	(116.841)	(147.388)	(257.456)
Cash flow generated from investing activities	162.914	159.452	288.814
Cash flow used in financing activities	(4.448)	(1.611)	(3.273)
Increase/decrease (-) in cash and cash equivalents	41.625	10.453	28.085
Effect of currency exchange rate fluctuation on cash and cash equivalents	6.459	(3.023)	(4.456)
Cash and cash equivalents at the end of the period	135.952	71.669	87.868
Financial investments at the end of the period	2.103.597	3.019.835	2.910.180
Total financial investments and cash and cash equivalents at the end of the period	2.239.549	3.091.504	2.998.048
FINANCIAL RATIOS
Number of shares issued at the end of the period	65.897.071	65.897.071	65.897.071
Basic and diluted earnings/loss (-) per share	0,25	(3,93)	4,87
Share price at the end of the period (in €)	26,22	23,76	28
Total group employees at the end of the period (number)	196	558	452

(*) The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to the increase or decrease in the cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:
• the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (-) financing activities
• the net proceeds or cash used, if any, related to the acquisitions or disposals of businesses; the acquisition of financial assets held at fair value through other comprehensive income; the movement in restricted cash and movement in financial investments, if any, the cash advances and loans given to third parties, if any, included in the net cash flows generated from/used in (-) investing activities
• the cash used for other liabilities related to the acquisition or disposal of businesses, if any, included in the net cash flows generated from/used in (-) operating activities
• the cash used for the purchase of own shares.